Liposomal Doxorubicin

Phase 3Small molecule

Eli Lilly

Liposomal Doxorubicin is one of 378 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

377

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Malignant Pleural MesotheliomaActive, not recruiting

Ovarian CarcinomaActive, not recruiting

Fallopian Tube CancerActive, not recruiting

Endometrial CarcinomaActive, not recruiting

Breast CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Ovarian CancerActive, not recruiting

GlioblastomaActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

LymphomaPhase 1

Active, not recruiting

Malignant Pleural MesotheliomaPhase 2

Active, not recruiting

Ovarian CarcinomaPhase 2

Active, not recruiting

Fallopian Tube CancerPhase 1/Phase 2

Active, not recruiting

Endometrial CarcinomaPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 3

Active, not recruiting

GlioblastomaPhase 2

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 2

Active, not recruiting

Showing 10 of 17 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Liposomal Doxorubicin

Eli Lilly

Phase 3

12 2

Tecentriq

Roche

Preclinical

36 3

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Chirocaine

PPurdue Pharma LP

Preclinical

1 7

Paracetamol

GSK

Preclinical

1 8

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—9

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 10

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Glioblastoma

NCT05864534

Phase 2Recruiting

Hodgkin Lymphoma

NCT03618550

Q4 2026

Phase 2Active, not recruiting

Lymphoproliferative Disorder

NCT00092222

Phase 2Not yet recruiting

First-Line Treatment

NCT06694324

Phase 1Recruiting

Liposomal Doxorubicin

NCT05210374

Q4 2027

Phase 3Active, not recruiting

Breast Cancer

NCT04895358

Clinical

Trials by Indication[1]

Breast Cancer12 trials

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04895358·340 enrolled

Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00465673·2 enrolled

A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging

Unknown status·—·Phase 4·NCT00531973·80 enrolled

Show 9 more trials

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting·LLaura Huppert, MD, BA·Phase 2·NCT03971409·150 enrolled

Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy

Completed·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University··NCT04258163·760 enrolled

Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

Completed·SSpanish Breast Cancer Research Group·Phase 2·NCT00258960·49 enrolled

Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193037·102 enrolled

CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer

Withdrawn·NNational Cancer Institute, Naples·Phase 2·NCT00434031

Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin

Terminated·CClaudia Lorenz-Schlüter·Phase 2·NCT00691912·26 enrolled

Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer

Completed·SSOLTI Breast Cancer Research Group·Phase 2·NCT01669239·83 enrolled

A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer

Completed·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 2·NCT02488564·49 enrolled

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT01333423

Ovarian Cancer9 trials

Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00628251·97 enrolled

Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03539328·138 enrolled

MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 3·NCT00326456·820 enrolled

Show 6 more trials

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Completed· Roche logo

Roche·Phase 3·NCT00976911·361 enrolled

Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer

Terminated·TTelik·Phase 3·NCT00350948·244 enrolled

A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00913835·125 enrolled

DOXIL for Consolidation Therapy in Ovarian Cancer.

Completed·SSoutheastern Gynecologic Oncology·Phase 2·NCT00248248·45 enrolled

S9912 Combination Chemo in Stage III Ovarian Cancer,

Completed·SSWOG Cancer Research Network·Phase 2·NCT00003896·68 enrolled

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

Completed·SSanta Maria Biotherapeutics·Phase 1·NCT02262455·32 enrolled

Liposomal Doxorubicin5 trials

Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00923936·16 enrolled

Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)

Completed· AbbVie logo

AbbVie·Phase 1/2·NCT00635193·138 enrolled

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

Recruiting·—·Phase 1·NCT05210374·24 enrolled

Show 2 more trials

Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·N/A·NCT00720096·4 enrolled

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02659930·62 enrolled

Lymphoma4 trials

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

Unknown status·NNanfang Hospital, Southern Medical University·Phase 3·NCT03023358·174 enrolled

A Registry Study in Lymphoma Patients Treated With Liposomal Doxorubicin

Unknown status·RRuijin Hospital··NCT04069845·2,000 enrolled

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

Not yet recruiting·—·Phase 2·NCT07021989·38 enrolled

Show 1 more trial

Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas

Withdrawn·LLudwig Institute for Cancer Research·Phase 1·NCT01490047

Multiple Myeloma3 trials

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT02186834·28 enrolled

Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma

Completed·WWeill Medical College of Cornell University·Phase 2·NCT00148317·38 enrolled

Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01078441·2 enrolled

23 more indications

Advanced Cancer2 trials

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Terminated·WWestern Regional Medical Center·Phase 1/2·NCT02331251·81 enrolled

Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00507962·51 enrolled

Breast Neoplasms2 trials

An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06312176·1,200 enrolled

An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07060807·1,000 enrolled

First-line Treatment1 trial

First-line Treatment of Advanced/unresectable DDLPS

Not yet recruiting·FFudan University·Phase 2·NCT06694324·49 enrolled

Endometrial Carcinoma1 trial

END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin

Completed·NNational Cancer Institute, Naples·Phase 2·NCT00401635·42 enrolled

Minimal Residual Disease1 trial

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01215344·36 enrolled

Primary Peritoneal Cancer1 trial

A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00191607·162 enrolled

Primary Peritoneal Carcinoma1 trial

Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00179725·60 enrolled

Combination Therapy1 trial

Combination Therapy of Anthracyclines for Children With Nephroblastoma

Not yet recruiting·SShengjing Hospital·Phase 4·NCT03892330·120 enrolled

Glioblastoma1 trial

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Recruiting·NNorthwestern University·Phase 2·NCT05864534·25 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 2·NCT00575406·94 enrolled

Advanced Solid Tumors1 trial

A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)

Terminated·TTesaro, Inc.·Phase 1·NCT01110603·12 enrolled

Patients With Advanced Solid Tumors1 trial

Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01214668·31 enrolled

Malignant Pleural Mesothelioma1 trial

Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma

Unknown status·NNational Institute of Cancerología·Phase 2·NCT00886028·31 enrolled

Pancreatic Cancer1 trial

Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer

Terminated·UUniversity of Iowa·Phase 2·NCT00426127·2 enrolled

Advanced Solid Tumours1 trial

AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT00819221·44 enrolled

Chemotherapy1 trial

Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy

Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT05097248·52 enrolled

Ovarian Carcinoma1 trial

Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma

Terminated·HHellenic Oncology Research Group·Phase 2·NCT00758732·34 enrolled

Fallopian Tube Cancer1 trial

Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00903630·15 enrolled

Lymphoproliferative Disorder1 trial

Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT00092222·75 enrolled

Metastatic Ewing Sarcoma1 trial

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT07194044·15 enrolled

KSHV Inflammatory Cytokine Syndrome (KICS)1 trial

Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT01419561·140 enrolled

Epithelial Ovarian Cancer1 trial

A Phase III Randomized Controlled Clinical Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Not yet recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 3·NCT07545460·404 enrolled

Hodgkin Lymphoma1 trial

Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03618550·257 enrolled

Sources

References

[1]
ClinicalTrials.gov — 58 trial records for Liposomal Doxorubicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Liposomal Doxorubicin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Liposomal Doxorubicin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Eli Lilly

Liposomal Doxorubicin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q4 2027

Trials by Indication[1]

Breast Cancer12 trials

Ovarian Cancer9 trials

Liposomal Doxorubicin5 trials

Lymphoma4 trials

Multiple Myeloma3 trials

Advanced Cancer2 trials

Breast Neoplasms2 trials

First-line Treatment1 trial

Endometrial Carcinoma1 trial

Minimal Residual Disease1 trial

Primary Peritoneal Cancer1 trial

Primary Peritoneal Carcinoma1 trial

Combination Therapy1 trial

Glioblastoma1 trial

Diffuse Large B-Cell Lymphoma1 trial

Advanced Solid Tumors1 trial

Patients With Advanced Solid Tumors1 trial

Malignant Pleural Mesothelioma1 trial

Pancreatic Cancer1 trial

Advanced Solid Tumours1 trial

Chemotherapy1 trial

Ovarian Carcinoma1 trial

Fallopian Tube Cancer1 trial

Lymphoproliferative Disorder1 trial

Metastatic Ewing Sarcoma1 trial

KSHV Inflammatory Cytokine Syndrome (KICS)1 trial

Epithelial Ovarian Cancer1 trial

Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News